Current trials | Chris O'Brien Lifehouse

Current Recruiting Clinical Trials

If you wish to participate in a clinical trial, speak with your treating oncologist or GP to see if there are current trials you may be suitable for.

If  you cannot find a suitable trial under your specific cancer type, please refer to “Solid Tumours and Phase 1 Studies” for trials including multiple cancer types.

There are currently no trials actively recruiting to this stream. Please refer to “Solid Tumours and Phase 1 Studies” for trials including multiple cancer types.

  • TRIAL REFERENCE:  LH16.037 PCR-MIB
    SUMMARY: Clinical Study No. [ANZUP 1502], Phase II study of Pembrolizumab with ChemoRadiotherapy as treatment for muscle invasive bladder cancer protocol
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR
    SUMMARY: Clinical Study JNJ42756493 : a Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.003 NUTMEG
    SUMMARY:  A Randomised Phase II Study of NivIUmab and TeMozolomide alone in newly diagnosed Elderly patients with Glioblastoma (NUTMEG)
    LEAD INVESTIGATOR: Prof John Simes
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.029 WinPro
    SUMMARY: An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer.
  • LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.043 AB928-CSP0002
    SUMMARY: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies.
    LEAD INVESTIGATOR: Dr Chen Lee
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.009 MK3475-756
    SUMMARY: A Randomised, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Rick Early Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (Keynote 756
    LEAD INVESTIGATOR: Dr Jane Beith
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.011 CHARIOT  BCT -1702
    SUMMARY: A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab
    LEAD INVESTIGATOR: Dr Jane Beith
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.050 CANNABIS
    SUMMARY: CTC0146 : Pilot and definitive randomised double-blind, placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (The CannabisCINV study)
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH15.055 ASCOLT (AG0213CR)
    SUMMARY: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre Double Blind, Randomised Placebo Controlled Phase III Trial (ASCOLT Trial)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.027 SPAR
    SUMMARY: A randomized, placebo-controlled phase II trial of Simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH13.015 AG0407GR
    SUMMARY:A randomised phase II/III trial of operative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer ( TOP GEAR : Trial Of Posteoperative therapy for Gastric and Esophagogastic junction AdenocaRcinoma)
    LEAD INVESTIGATOR:Dr Regina Tse
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR
    SUMMARY: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations.
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.042 AB928-CSP0003
    SUMMARY: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies.
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.043 AB928-CSP0002
    SUMMARY: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies.
    LEAD INVESTIGATOR: Dr Chen Lee
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.016 INOVATe
    SUMMARY: Individualised Ovarian Cancer treatment through Integration of Genomic Pathology into Multidisciplinary Care.
    Intensive molecular testing on primary tumours, samples collected at relapse (ascites and biopsies) and circulating tumour DNA. Genomic biomarkers to predict treatment response will be assessed and molecular testing will be used to assist in the selection of patients for clinical trials of targeted agents. Patients will be separately consented for any HREC-approved trial for which they are found to be eligible.
    LEAD INVESTIGATOR: Dr Philip Beale
    ADDITIONAL INFORMATION:  Inclusion & Exclusion Criteria

Investigated for, or diagnosed with ovarian, fallopian or primary peritoneal cancer

Age greater than 18 years old

Capable of giving informed consent

         REFER A PATIENT: Click here

  • TRIAL REFERENCE:  LH19.010 SOLACE 2
    SUMMARY: A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects” SOLACE 2
    LEAD INVESTIGATOR: Dr Philip Beale
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH14.021 ANZUP 1302
    SUMMARY:  Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk metastatic germ cell tumours (P3BEP Trial)
    LEAD INVESTIGATOR:  A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.021 TIGER
    SUMMARY:  A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
    LEAD INVESTIGATOR: A/Prof Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.008 H&N – Nurse Practioners
    SUMMARY: Phase I non-randomised open-label clinical trial of safety and feasilbilty of topical dexamethasone/hyaluronic acid formulation to exposed facial nerve branches during surgery
  • LEAD INVESTIGATOR: Dr Jonathan Clark
    REFER A PATIENT: Click here

 

  • TRIAL REFERENCE:  LH19.018 PSI 617-101
    SUMMARY: Phase 1b/2, Multicenter, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer’
  • LEAD INVESTIGATOR: Dr Mun Hui
    REFER A PATIENT: Click here

 

  • TRIAL REFERENCE:  LH19.026 MK3475-630
    SUMMARY: Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advances Cutaneous Squamous Cell Carcinoma
  • LEAD INVESTIGATOR: Dr Michael Boyer
  • ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here

 

  • TRIAL REFERENCE:  LH17.019 EnRICH
    SUMMARY: Embedding Research (and Evidence) in Cancer Healthcare (EnRICH)
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.046 OSCILLATE
    SUMMARY: A Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer
    LEAD INVESTIGATOR: Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.058 AMG 757
    SUMMARY: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer’ 20160323
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.060 MK3475-598
    SUMMARY: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.024 MK3475-789
    SUMMARY: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.025 BO40336 (ALINA)
    SUMMARY: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
    LEAD INVESTIGATOR: Dr Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.017 61186372EDI1001
    SUMMARY: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMET Anitbody, in Subjects with Advanced Non-Small Cell Lung Cancer
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here

There are currently no trials actively recruiting to this stream. Please refer to “Solid Tumours and Phase 1 Studies” for trials including multiple cancer types.

  • TRIAL REFERENCE:  LH16.052 SHR3680
    SUMMARY: A phase I trial of SHR3680 in subjects with metastatic castration-resistant prostate cancer as monotherapy
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.062 GALAHAD
    SUMMARY: Clinical Study No. 64091742PCR2001 : A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.044 GSK204697/PXL230779
    SUMMARY: Clinical Study No. 204697 – a phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprevation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.011 CA209-9KD
    SUMMARY: A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD:CHECKpoint pathway and nivoluMAb clinical Trials Evaluation 9KD)
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.031 LEEP
    SUMMARY: A Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.003 JPCM_Prostate
    SUMMARY: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of  Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostrate Cancer
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.005  AMG 160
    SUMMARY: A Phase 1 Study evaluating the Safety ,Tolerability, Pharmacokinteics and Efficacy of Prostate Specific Membrane Antigen Half-Lie Extended Bispecific T-cell Engager AMG 160 in subjects with metastatic Castration-resistant Prostate Canver
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.022 C3441021
    SUMMARY: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Background Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With DNA Damage Repair Deficiencies
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.030 CX839-008 (Calithera/CANTATA)
    SUMMARY: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) – CANTATA
    LEAD INVESTIGATOR: Dr Michelle Harrison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.033 RENO 26 JX594
    SUMMARY: Clinical Study No. JX594-REN026. A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactived Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC)
    LEAD INVESTIGATOR: Dr Michelle Harrison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.045 CA209-933ISR
    SUMMARY: Nivolumab in renal transplant recipients with poor prognosis cancers – a safety study.
    LEAD INVESTIGATOR: Prof Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.038 EZH-202
    SUMMARY: Clinical Study No. EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
    LEAD INVESTIGATOR: David Thomas
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.023 SU2C-SARC-032
    SUMMARY: SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
    LEAD INVESTIGATOR: A/Prof Angela Hong
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.007  NORTH
    SUMMARY: A Phase III Study of Panobinostat in Paediatric, Adolescent and Young Adult patients with Solid Tumors including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.019 rECCUr
    SUMMARY: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
    LEAD INVESTIGATOR: Dr Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.005 MK-3475-158
    SUMMARY: Clinical Study No. MK-3475-158 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
    LEAD INVESTIGATOR: Steven Kao
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.030 D6070C00001
    SUMMARY: A Phase 1 Multicenter, Open-Label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH16.052 SHR3680
    SUMMARY: A phase I trial of SHR3680 in subjects with metastatic castration-resistant prostate cancer as monotherapy
    LEAD INVESTIGATOR: Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.040 MGA 012
    SUMMARY: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors
    LEAD INVESTIGATOR: Vivek Bhadri
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.044 GSK204697/PXL230779
    SUMMARY: A phase IB open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprevation therapy and other agents in subjects with castrate-resistant prostate cancer (CRPC)
    LEAD INVESTIGATOR: Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.050 APG 1252
    SUMMARY: A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or Other Solid Tumors
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.053 MK7684-001
    SUMMARY: A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumours
    LEAD INVESTIGATOR: Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.058 AMG 757
    SUMMARY: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer’ 20160323
    LEAD INVESTIGATOR: Michael Boyer
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.020 B9991023
    SUMMARY: A Multicentre open labe; Phase 1B/2 study to evaluate safety & efficacy of Avelumab (MSB0010718C) in combination with Chemotherapy with or without other anti-cancer immunotherapies as first line treatment in patients with advanced malignancies
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.021 TIGER TICE
    SUMMARY: A randomised Phase III trial comparing conventional dose chemotherapy using paclitaxel, ifosfamide & cisplatin (TIP) with high dose chemptherapy using mobilising paclitaxel plus ifosfamide followed by high dose carboplatin & etoposide (TI-CE) as first salvage treatment in relapsed or refactory germ cell tumors
    LEAD INVESTIGATOR: Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.042 AB928-CSP0003
    SUMMARY: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies.
    LEAD INVESTIGATOR: Prof Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.043 AB928-CSP0002
    SUMMARY: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies.
    LEAD INVESTIGATOR: Dr Chen Lee
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.004 FPT155-001
    SUMMARY: A Phase 1a/1b Study of FPT155 in patients with advanced Solid Tumors
    LEAD INVESTIGATOR: Dr Lisa Horvath
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.008 MK3475-587
    SUMMARY: A Multi-center, Open label, Phase III Extension Trial to Study the Long-term   Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
    LEAD INVESTIGATOR: Dr Catriona McNeil
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.020 AB154CSP0001
    SUMMARY: A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.024 AMG 404
    SUMMARY: A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients with Advanced Solid Tumors’
    LEAD INVESTIGATOR: Dr Mun Hui
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH19.026 MK3475-630
    SUMMARY: Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advances Cutaneous Squamous Cell Carcinoma
  • LEAD INVESTIGATOR: Dr Michael Boyer
  • ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH17.052 CO40016
    SUMMARY: A Double-Blind, Placebo-Controlled, Randomised Phase III Study Of Ipatasertib In Combination With Paclitaxel As A Treatment For Patients With Pik3ca/Akt1/Pten-Altered, Locally Advanced Or Metastatic, Triple-Negative Breast Cancer Or Hormone Receptor – Positive, Her2-Negative Breast Cancer
    LEAD INVESTIGATOR: A/Prof Jane Beith
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
  • TRIAL REFERENCE:  LH18.040 THOR – JNJ 42756493
    SUMMARY: Clinical Study JNJ42756493 : a Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene
    LEAD INVESTIGATOR: Professor Peter Grimison
    ADDITIONAL INFORMATION: Inclusion & Exclusion Criteria
    REFER A PATIENT: Click here
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search